DNa damage and repair pathway profiles as biomarkers in high-risk prostate cancer
Menée sur une cohorte de 1 090 patients atteints d'un cancer de la prostate à risque élevé de récidive et traités par prostatectomie (âge moyen au diagnostic : 65,3 ans), cette étude évalue l'association entre une signature basée sur un profil d'expression de gènes impliqués dans les processus de réparation de l'ADN et la survie des patients
A major challenge for clinicians in the management of prostate cancer is distinguishing patients with indolent disease from those with aggressive lethal variants of the disease at diagnosis. The ability to discriminate between these groups will simultaneously allow clinicians to avoid overtreatment of indolent disease and intensify treatment in men with aggressive disease, as well as identify them as candidates for future biomarker-driven clinical trials. In response to this need, several genomic biomarker tests assessing the likelihood of aggressive prostate cancer have recently been brought to the market, including Decipher (GenomeDx Biosciences), OncotypeDX (Genomic Health), and Prolaris (Myriad Genetics).1 In the year that the 2015 Albert Lasker Basic Medical Research Award was awarded for discoveries concerning the DNA damage response, it is fitting that Evans and colleagues2 report in this issue of JAMA Oncology that patient level DNA damage and repair (DDR) pathway profiles are prognostic after prostatectomy for high-risk prostate cancer.
JAMA Oncology , commentaire, 2015